Cretostimogene reduces NMIBC recurrence risk by 68% in Phase 3 PIVOT-006, company reports

Phase 3 RCT · Dealroom · 2026-11-16. Number 2 in the UrologyWatch Top 5 for November 17, 2026.

CG Oncology announced topline results from its Phase 3 PIVOT-006 trial, reporting that cretostimogene reduced recurrence risk by 68% in NMIBC patients, with no patients discontinuing treatment due to related side effects. Full data and statistical details have not yet been disclosed.

Why it matters: A company-reported Phase 3 topline result suggests cretostimogene may offer a new intravesical option for NMIBC, pending full data disclosure and FDA review.

Source: Dealroom

The full November 17, 2026 edition · Today's urology news

Loading today's edition…